News | August 01, 2025
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Subscribe To Our Newsletter & Stay Updated
